NewsBenzinga据报道,argenx计划在2026年底前就efgartigimod用于IMNM提交补充BLA,因III期ALKIVIA研究显示其在第52周较安慰剂带来高14.8分的TIS改善 据报道,argenx计划在2026年底前就efgartigimod用于IMNM提交补充BLA,因III期ALKIVIA研究显示其在第52周较安慰剂带来高14.8分的TIS改善 Benzinga 2026.11.09 08:42 (GMT+0) Open on Benzinga Other news TD Cowen Maintains Buy Rating on Sharplink With $13 Price Target Tencent's Q3 Revenue Up 8% YoY to RMB 207.3 Billion Realty Income vs. Agree Realty: Which REIT Wins on Dividends and Growth? Salesforce Issues Security Advisory On Third-Party Optimizely Script Incident Affecting Certain Salesforce-Branded Sites; Optimizely Scripts Being Confirmed Disabled FBI Reissues Warning About AI-Powered Cyberattacks on Businesses as Crypto Bettors Dismiss AI Link to FAA Outage Is Wall Street Bullish or Bearish on Solventum Stock?
Salesforce Issues Security Advisory On Third-Party Optimizely Script Incident Affecting Certain Salesforce-Branded Sites; Optimizely Scripts Being Confirmed Disabled
FBI Reissues Warning About AI-Powered Cyberattacks on Businesses as Crypto Bettors Dismiss AI Link to FAA Outage